Martin Investment Management LLC trimmed its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 309,507 shares of the company’s stock after selling 10,352 shares during the quarter. Astrazeneca accounts for approximately 14.2% of Martin Investment Management LLC’s investment portfolio, making the stock its largest holding. Martin Investment Management LLC’s holdings in Astrazeneca were worth $54,318,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Bank of America Corp DE lifted its position in shares of Astrazeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Astrazeneca by 2.1% in the fourth quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock valued at $3,791,051,000 after acquiring an additional 438,709 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after acquiring an additional 582,183 shares in the last quarter. Holocene Advisors LP raised its holdings in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Astrazeneca by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock valued at $438,342,000 after acquiring an additional 660,569 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently weighed in on AZN shares. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Monday. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday. Finally, Weiss Ratings initiated coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Astrazeneca Price Performance
Shares of AZN stock opened at $179.90 on Tuesday. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The firm has a market capitalization of $279.01 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 1.48 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock’s 50-day simple moving average is $191.20 and its 200-day simple moving average is $184.28.
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, equities analysts forecast that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
